Consider the awkward moment after a scientific discovery. The experiment has worked. The paper has a future. But who recruits the chief executive, assembles the investors, and decides what must happen before a medicine can reach a patient? AN Venture Partners has built an investment firm around that handoff.
- Find science in Japan and help build companies around it.
- Bring US operating experience and global financing to the work.
- Prepare researchers for commercialization before the investor pitch.
A scientist, a mentor, a company
Take Yoshikazu Nakaoka, a researcher at Japan’s National Cerebral and Cardiovascular Center. He was a finalist in the first Science2Startup Japan program in 2024. His mentor was Andrew Levin, then at RA Capital Management. The relationship helped produce PAhR Therapeutics, a company developing treatments for pulmonary arterial hypertension. By the following year, it had raised $14 million in seed financing.
That sequence matters. The scientific work came first, followed by a relationship that helped turn it into a company investors could finance. AN Venture, which founded the Japanese program and invested in PAhR, operates in precisely this space. Its contribution begins where a laboratory’s usual responsibilities end.
The firm’s shorthand is almost stubbornly plain: source, build, finance. Find promising science in Japan. Help create companies using the US biotech ecosystem. Bring other investors into the financing. Each verb names a separate job. A discovery does not automatically supply the people capable of doing the next one.
The missing machinery
The diagnosis predates the fund’s final close. In December 2023, Japan Investment Corporation described a country rich in promising basic research but short of the private capital needed to commercialize it. Its announcement also pointed to a startup support system less developed than those in Europe and the United States. JIC committed $30 million at AN Venture’s initial fund closing.
AN Venture was established in 2022 in alliance with ARCH Venture Partners. Founder and managing partner Ken Horne brought experience as an entrepreneur and healthcare investor. His earlier work included founding or leading Aline Aesthetics, Symic Bio, and Teon Therapeutics. This is a firm built around the practical business of getting companies started.
The team connects several kinds of expertise. Ari Nowacek is a partner at both AN Venture and ARCH. Takashi Futami brings pharmaceutical research and venture experience. Jun Hashimoto adds financial and operational support. Former Pfizer research chief Mikael Dolsten joined as an advisor in August 2025, adding drug-development experience to the network.
“I have always admired the strength and depth of Japanese science”
Mikael Dolsten · August 2025
Two sides of the investment table
Who is the customer? For a venture firm, the answer runs in two directions. Limited partners supply the fund’s capital and seek investment returns. Scientists and biotech founders receive financing and help building businesses. Pharmaceutical companies may appear on either side, as fund investors or as future partners for a portfolio company.
AN Venture’s first fund closed at $200 million in June 2025. More than 20 limited partners participated, including JIC, Shionogi, Otsuka Pharmaceutical, MUFG Bank, and Sumitomo Mitsui Banking Corporation. The fund has a ten-year term. Its mandate spans pre-proof-of-concept research through advanced clinical development.
Capital committed by limited partners to the fund. Portfolio company financings below are separate transactions.
That scope gives the firm room to work with academic discoveries, pharmaceutical spinouts, and more mature development programs. Its distinction is the combination of Japanese sourcing and hands-on company creation linked to US talent and international investors. Remiges Ventures’ RDiscovery platform also pursues drug-discovery incubation. AN Venture’s strategy belongs to an existing field of specialist company builders.
A portfolio that makes the argument
Typewriter Therapeutics offers a particularly clear example. Its gene-writing technology builds on R2 retrotransposon research associated with University of Tokyo professor emeritus Haruhiko Fujiwara. In September 2026, Typewriter emerged from stealth with a $56 million Series A co-led by AN Venture and RA Capital Management. Horne continued as board chair.
The company has research facilities in Tokyo and Cambridge, Massachusetts. Its initial focus includes in vivo CAR T medicines and genetic liver diseases. Here, the cross-border arrangement has a concrete shape: Japanese scientific roots, research on both sides of the Pacific, a recruited leadership team, and a financing syndicate.
The portfolio also reaches beyond newly formed platforms. Tortugas Neuroscience, announced as an investment in April 2026, develops clinical-stage assets licensed from Eisai and Hansoh. Crystalys Therapeutics is advancing dotinurad, a gout medicine invented by Japan’s Fuji Yakuhin. AN Venture participated in Crystalys’s $130 million Series B announced in July.
In October, City Therapeutics became AN Venture’s first portfolio company to complete an IPO. City develops RNA interference medicines and counts scientists Yukihide Tomari and Kotaro Nakanishi among its co-founders. Its Nasdaq debut supplies a visible company-building milestone. The listing alone does not establish what AN Venture’s investors have earned.
For a founder weighing this kind of investor, the practical question is which part of company building needs help. A research team may need operating leadership; an established company may need a larger financing syndicate. AN Venture’s broad stage mandate accommodates both conversations. Its portfolio makes the distinction visible: a gene-writing platform and a medicine already being developed internationally can fit the same investment thesis because the connection is Japanese science, rather than one disease or one technology.
The paragraph before the pitch
For a researcher, the most accessible part of this story is S2S Japan. Its published process starts with a one-paragraph proposal, then moves through slides, interviews, selection, and matched mentorship. Finalists refine their ideas before presenting. The third symposium is scheduled for November 12, 2026, in Tokyo.
The useful lesson is the order of operations. Bring experienced people into the conversation while the commercialization plan can still change. Define what the science needs, then build the team and financing around those needs. This approach depends on credible research, workable intellectual property, and investors willing to wait through development. An international network cannot make a therapy safe or effective. It can help assemble the company responsible for finding out.